These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 31449501

  • 1. PSMA PET/CT for staging and treatment of prostate cancer.
    Hofman M.
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):370-373. PubMed ID: 31449501
    [No Abstract] [Full Text] [Related]

  • 2. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
    Mottaghy FM, Heinzel A, Verburg FA.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ, Lee SW, Ha HK.
    Urol Int; 2019 Jul; 102(1):27-36. PubMed ID: 30269140
    [Abstract] [Full Text] [Related]

  • 6. Incidentally Detected 18F-PSMA Uptake in Glomus Jugulare.
    Zade A, Trivedi C, Ingule A, Jha S, Agrwal A.
    Clin Nucl Med; 2020 Aug; 45(8):e360-e362. PubMed ID: 32520502
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
    Ravi Kumar AS, Lawrentschuk N, Hofman MS.
    Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M, Fendler WP, Czernin J, Herrmann K.
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.
    Aragon-Ching JB.
    Asian J Androl; 2021 Nov; 23(1):1-2. PubMed ID: 32719192
    [No Abstract] [Full Text] [Related]

  • 16. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R, Koncz M, Luetzen U, Krause F, Dunst J.
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.
    Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, Pomper MG, Lotan TL, Ross AE.
    Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.